VALBIOTIS Receives US and European TOTUM-070 Patent for Reducing Hypercholesterolemia
14 Settembre 2020 - 5:40PM
Business Wire
- TOTUM-070 exclusivity guaranteed in the United States and in
Europe for reducing blood LDL-cholesterol levels, a cardiovascular
disease risk factor;
- Intellectual property rights protecting the composition of the
TOTUM-070 active substance for food and pharmaceutical
applications;
- A milestone in the further development of TOTUM-070, in the
search for commercial partnerships and in receiving approval for
health claims in Europe and North America.
Regulatory News:
VALBIOTIS (Paris:ALVAL) (FR0013254851 - ALVAL, eligible for the
PEA/SME), a Research & Development company committed to
scientific innovation for preventing and combating metabolic
diseases, has announced that it has obtained an American and
European patent for TOTUM-070, its active substance dedicated to
reducing LDL-cholesterol in the blood (“bad cholesterol”).
TOTUM-070 is a combination of plant extracts that contains
neither phytosterols nor red yeast rice, designed by VALBIOTIS’
proprietary R&D platform based in Riom (63). The patent has
been granted for the United States, Europe and South Africa.
TOTUM-070 targets excess LDL-cholesterol, which is a well-known
risk factor for cardiovascular disease and the main cause of
atherosclerosis1. It is believed that over 174 million adults in
the US and Europe will suffer from hypercholesterolemia in 2020.
The market for non-prescription products is estimated at €1.2
billion in these regions2.
Sébastien Peltier, CEO of VALBIOTIS, said: “With
TOTUM-070, we are targeting a major market, one in which we stand
out for our specific plant know-how, a high level of clinical
evidence and robust intellectual property worldwide. This strategy
has already borne fruit, with a major partnership aiming at
developping and marketing our first active substance, TOTUM-63.
Obtaining this patent for TOTUM-070 in regions where populations
are particularly affected by hypercholesterolemia marks a milestone
in our development model aimed at building new partnerships of this
scale.”
The TOTUM-070 patent covers a wide range of food and
pharmaceutical applications relating to lipid metabolism disorders,
for example dyslipidemia, cholesterol and triglycerides. It is the
focus of an international filing strategy reaching beyond the
United States and Europe.
A Phase II clinical study evaluating the efficacy of TOTUM-070
in people with untreated moderate hypercholesterolemia will be
launched before the end of the year. The initiation of this study
will be communicated subsequently. The objective for VALBIOTIS is
to obtain the first proprietary health claim for reducing
LDL-cholesterol, notably in Europe and North America, for a product
containing neither phytosterols nor red yeast rice.
ABOUT VALBIOTIS VALBIOTIS is a Research & Development
company committed to scientific innovation for preventing and
combating metabolic diseases in response to unmet medical needs.
VALBIOTIS has adopted an innovative approach, aiming to
revolutionize healthcare by developing a new class of nutritional
health solutions designed to reduce the risk of major metabolic
diseases, based on a multi-target approach and made possible by the
use of plant-based ingredients. Its products are intended to be
licensed to players in the health world. VALBIOTIS was founded in
La Rochelle in early 2014 and has formed numerous partnerships with
top academic centers. The Company has established three sites in
France – Périgny, La Rochelle (17) and Riom (63). VALBIOTIS is a
member of the "BPI Excellence" network and received the "Innovative
Company" status accorded by BPI France. VALBIOTIS has also been
awarded "Young Innovative Company" status and has received major
financial support from the European Union for its research programs
by obtaining support from the European Regional Development Fund
(ERDF). VALBIOTIS is a PEA-SME eligible company. Find out more
about VALBIOTIS: www.valbiotis.com
Name: Valbiotis ISIN code: FR0013254851 Mnemonic code: ALVAL
DISCLAIMER This press release contains forward-looking
statements about VALBIOTIS' objectives, based on rational
hypotheses and the information available to the company at the
present time. However, in no way does this constitute a guarantee
of future performance, and these projections can be reconsidered
based on changes in economic conditions and financial markets, as
well as a certain number of risks and doubts, including those
described in the VALBIOTIS core document, filed with the French
Financial Markets Regulator (AMF) on 31 July 2020 (application
number R20-018), these documents being available on the Company’s
website (www.valbiotis.com).
1 2018 Guideline on the Management of Blood Cholesterol, a
report from the American College of Cardiology / American Heart
Association, Journal Of The American College Of Cardiology, 2019. 2
AEC Partners data for the United States and VALBIOTIS’ 5 priority
European countries (Germany, Spain, France, Italy and the United
Kingdom), 2020.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200914005535/en/
CORPORATE COMMUNICATION / VALBIOTIS Carole ROCHER / Marc
DELAUNAY +33 5 46 28 62 58 media@valbiotis.com
FINANCIAL COMMUNICATION / ACTIFIN Stéphane RUIZ +33 1 56 88 11
14 sruiz@actifin.fr
Grafico Azioni Valbiotis (EU:ALVAL)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Valbiotis (EU:ALVAL)
Storico
Da Apr 2023 a Apr 2024